The cost-benefit ratio of the cure of Hodgkin's disease.
Ultmann
J E
JE
Section of Hematology-Oncology, University of Chicago Hospitals, Chicago, Illinois 60637, USA.
Ong
S T
ST
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D012008:Recurrence; D012307:Risk Factors
D000970:Antineoplastic Agents